English

Athira Pharma, Inc.

EDGAR

ATHA Quarterly report (10-Q) · filed 2026-08-14

42 filing records in this dataset, filed from 2020-08-26 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 32.3 million USD 2026-06-30 Source
Exact value

32323000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 9.42 million shares 2026-06-30 Source
Exact value

9421663 shares

Reported share-count change

-76.11% · -30 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

39439326 shares · 2025-06-30· Source
9421663 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-141 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -6611000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -105609000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -22720000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -32948000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -19007000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-61.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -26332000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21664000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -45729000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -26332000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -20903000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -37861000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -20903000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

33 thousand USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Capital expenditure: 5000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 33000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 5000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 33000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 33000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 33000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 33000 USD · 2024-01-01 – 2024-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 5 of 11 periods available· newest 2024-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 8.67 million

Prior period

−USD 96.94 million

2024-01-01 – 2024-12-31
Current period

−USD 105.61 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-105609000 − -96940000 = -8669000 USD

-96940000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-105609000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Athira Pharma, Inc. · 2025-12-31 Athira Pharma, Inc. (edgar:1620463) Year-over-year change in Net income: -8669000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -105609000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#3150033 Filing: 000119312526134565 Input fundies:NetIncome: -96940000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#3151981 Filing: 000119312526134565
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 51.44 million

Prior period

−USD 97.17 million

2024-01-01 – 2024-12-31
Current period

−USD 45.73 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-45729000 − -97170000 = 51441000 USD

-97170000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-45729000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Athira Pharma, Inc. · 2025-12-31 Athira Pharma, Inc. (edgar:1620463) Year-over-year change in Operating cash flow: 51441000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -45729000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#2034005 Filing: 000119312526134565 Input fundies:OperatingCashFlow: -97170000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#2035975 Filing: 000119312526134565
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 5.1 million Exact value Exact value: -5097000 USD 2018-01-01 – 2018-12-31: -5097000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2018-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -5097000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5097000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000156459021001397/atha-20210106.xml#213337 Filing: 000156459021001397 The citation records this snapshot. The page link may show a newer release later.	−USD 4.48 million Exact value Exact value: -4483000 USD 2018-01-01 – 2018-12-31: -4483000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2018-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -4483000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4483000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000156459021001397/atha-20210106.xml#225949 Filing: 000156459021001397 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 5.16 million Exact value Exact value: -5161000 USD 2019-01-01 – 2019-12-31: -5161000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2019-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -5161000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5161000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000156459021015495/atha-20201231.xml#140901 Filing: 000156459021015495 The citation records this snapshot. The page link may show a newer release later.	−USD 3.71 million Exact value Exact value: -3713000 USD 2019-01-01 – 2019-12-31: -3713000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2019-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -3713000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3713000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000156459021015495/atha-20201231.xml#161027 Filing: 000156459021015495 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 19.96 million Exact value Exact value: -19955000 USD 2020-01-01 – 2020-12-31: -19955000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2020-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -19955000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19955000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017022004782/atha-20211231.htm#3141473 Filing: 000095017022004782 The citation records this snapshot. The page link may show a newer release later.	−USD 24.11 million Exact value Exact value: -24113000 USD 2020-01-01 – 2020-12-31: -24113000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2020-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -24113000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24113000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017022004782/atha-20211231.htm#2117289 Filing: 000095017022004782 The citation records this snapshot. The page link may show a newer release later.	USD 2.32 million Exact value Exact value: 2320000 USD 2020-01-01 – 2020-12-31: 2320000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Athira Pharma, Inc. · 2020-12-31 Athira Pharma, Inc. (edgar:1620463) Capital Expenditure: 2320000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2320000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017022004782/atha-20211231.htm#2136243 Filing: 000095017022004782 The citation records this snapshot. The page link may show a newer release later.	−USD 26.43 million Calculation and evidence -24113000 − 2320000 USD Exact free cash flow: -26433000 USD 2020-01-01 – 2020-12-31: -24113000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2320000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Athira Pharma, Inc. · 2020-12-31 Athira Pharma, Inc. (edgar:1620463) Free cash flow: -26433000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24113000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017022004782/atha-20211231.htm#2117289 Filing: 000095017022004782 Input fundies:CapitalExpenditure: 2320000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017022004782/atha-20211231.htm#2136243 Filing: 000095017022004782 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 54.85 million Exact value Exact value: -54853000 USD 2021-01-01 – 2021-12-31: -54853000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2021-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -54853000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54853000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009498/atha-20221231.htm#2951172 Filing: 000095017023009498 The citation records this snapshot. The page link may show a newer release later.	−USD 43.1 million Exact value Exact value: -43098000 USD 2021-01-01 – 2021-12-31: -43098000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2021-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -43098000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43098000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009498/atha-20221231.htm#2108269 Filing: 000095017023009498 The citation records this snapshot. The page link may show a newer release later.	USD 1.57 million Exact value Exact value: 1573000 USD 2021-01-01 – 2021-12-31: 1573000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Athira Pharma, Inc. · 2021-12-31 Athira Pharma, Inc. (edgar:1620463) Capital Expenditure: 1573000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1573000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009498/atha-20221231.htm#2129773 Filing: 000095017023009498 The citation records this snapshot. The page link may show a newer release later.	−USD 44.67 million Calculation and evidence -43098000 − 1573000 USD Exact free cash flow: -44671000 USD 2021-01-01 – 2021-12-31: -43098000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1573000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Athira Pharma, Inc. · 2021-12-31 Athira Pharma, Inc. (edgar:1620463) Free cash flow: -44671000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43098000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009498/atha-20221231.htm#2108269 Filing: 000095017023009498 Input fundies:CapitalExpenditure: 1573000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017023009498/atha-20221231.htm#2129773 Filing: 000095017023009498 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 95.64 million Exact value Exact value: -95639000 USD 2022-01-01 – 2022-12-31: -95639000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2022-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -95639000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -95639000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018787/atha-20231231.htm#2212514 Filing: 000095017024018787 The citation records this snapshot. The page link may show a newer release later.	−USD 72.47 million Exact value Exact value: -72469000 USD 2022-01-01 – 2022-12-31: -72469000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2022-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -72469000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -72469000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018787/atha-20231231.htm#1663740 Filing: 000095017024018787 The citation records this snapshot. The page link may show a newer release later.	USD 1.14 million Exact value Exact value: 1141000 USD 2022-01-01 – 2022-12-31: 1141000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Athira Pharma, Inc. · 2022-12-31 Athira Pharma, Inc. (edgar:1620463) Capital Expenditure: 1141000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1141000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018787/atha-20231231.htm#1675347 Filing: 000095017024018787 The citation records this snapshot. The page link may show a newer release later.	−USD 73.61 million Calculation and evidence -72469000 − 1141000 USD Exact free cash flow: -73610000 USD 2022-01-01 – 2022-12-31: -72469000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1141000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Athira Pharma, Inc. · 2022-12-31 Athira Pharma, Inc. (edgar:1620463) Free cash flow: -73610000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -72469000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018787/atha-20231231.htm#1663740 Filing: 000095017024018787 Input fundies:CapitalExpenditure: 1141000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017024018787/atha-20231231.htm#1675347 Filing: 000095017024018787 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 117.67 million Exact value Exact value: -117672000 USD 2023-01-01 – 2023-12-31: -117672000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2023-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -117672000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -117672000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017025029069/atha-20241231.htm#2494631 Filing: 000095017025029069 The citation records this snapshot. The page link may show a newer release later.	−USD 100.75 million Exact value Exact value: -100753000 USD 2023-01-01 – 2023-12-31: -100753000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2023-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -100753000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -100753000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017025029069/atha-20241231.htm#1802677 Filing: 000095017025029069 The citation records this snapshot. The page link may show a newer release later.	USD 304,000 Exact value Exact value: 304000 USD 2023-01-01 – 2023-12-31: 304000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Athira Pharma, Inc. · 2023-12-31 Athira Pharma, Inc. (edgar:1620463) Capital Expenditure: 304000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 304000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017025029069/atha-20241231.htm#1817693 Filing: 000095017025029069 The citation records this snapshot. The page link may show a newer release later.	−USD 101.06 million Calculation and evidence -100753000 − 304000 USD Exact free cash flow: -101057000 USD 2023-01-01 – 2023-12-31: -100753000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 304000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Athira Pharma, Inc. · 2023-12-31 Athira Pharma, Inc. (edgar:1620463) Free cash flow: -101057000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -100753000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017025029069/atha-20241231.htm#1802677 Filing: 000095017025029069 Input fundies:CapitalExpenditure: 304000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000095017025029069/atha-20241231.htm#1817693 Filing: 000095017025029069 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 96.94 million Exact value Exact value: -96940000 USD 2024-01-01 – 2024-12-31: -96940000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2024-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -96940000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -96940000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#3151981 Filing: 000119312526134565 The citation records this snapshot. The page link may show a newer release later.	−USD 97.17 million Exact value Exact value: -97170000 USD 2024-01-01 – 2024-12-31: -97170000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2024-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -97170000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -97170000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#2035975 Filing: 000119312526134565 The citation records this snapshot. The page link may show a newer release later.	USD 33,000 Exact value Exact value: 33000 USD 2024-01-01 – 2024-12-31: 33000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Athira Pharma, Inc. · 2024-12-31 Athira Pharma, Inc. (edgar:1620463) Capital Expenditure: 33000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 33000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#2050991 Filing: 000119312526134565 The citation records this snapshot. The page link may show a newer release later.	−USD 97.2 million Calculation and evidence -97170000 − 33000 USD Exact free cash flow: -97203000 USD 2024-01-01 – 2024-12-31: -97170000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 33000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Athira Pharma, Inc. · 2024-12-31 Athira Pharma, Inc. (edgar:1620463) Free cash flow: -97203000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -97170000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#2035975 Filing: 000119312526134565 Input fundies:CapitalExpenditure: 33000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#2050991 Filing: 000119312526134565 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 105.61 million Exact value Exact value: -105609000 USD 2025-01-01 – 2025-12-31: -105609000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Athira Pharma, Inc. · 2025-12-31 Athira Pharma, Inc. (edgar:1620463) Net Income: -105609000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -105609000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#3150033 Filing: 000119312526134565 The citation records this snapshot. The page link may show a newer release later.	−USD 45.73 million Exact value Exact value: -45729000 USD 2025-01-01 – 2025-12-31: -45729000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Athira Pharma, Inc. · 2025-12-31 Athira Pharma, Inc. (edgar:1620463) Operating Cash Flow: -45729000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:37:27Z Snapshot: ed592d70b77622b98464f5942aea7cb7841e582a766f266a2669775e8a1fc943 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1620463/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45729000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/lona-20251231.htm#2034005 Filing: 000119312526134565 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

42 filings · 1,372 latest values · 1,372 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001620463, 1620463, ATHA, LONA, edgar:1620463

Also known as ATHIRA PHARMA, INC., Athira Pharma, Inc., LeonaBio, Inc., M3 Biotechnology, Inc.

Athira Pharma, Inc.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation